Suppr超能文献

肺超声引导下液体复苏对 ICU 患者通气时间的影响(CONFIDENCE):一项多中心随机对照试验方案。

Effect of lung ultrasound-guided fluid deresuscitation on duration of ventilation in intensive care unit patients (CONFIDENCE): protocol for a multicentre randomised controlled trial.

机构信息

Department of Intensive Care, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands.

Amsterdam Leiden Intensive care Focused Echography (ALIFE, www.alifeofpocus.com ), Amsterdam, The Netherlands.

出版信息

Trials. 2023 Mar 24;24(1):226. doi: 10.1186/s13063-023-07171-w.

Abstract

BACKGROUND

Fluid therapy is a common intervention in critically ill patients. It is increasingly recognised that deresuscitation is an essential part of fluid therapy and delayed deresuscitation is associated with longer invasive ventilation and length of intensive care unit (ICU) stay. However, optimal timing and rate of deresuscitation remain unclear. Lung ultrasound (LUS) may be used to identify fluid overload. We hypothesise that daily LUS-guided deresuscitation is superior to deresuscitation without LUS in critically ill patients expected to undergo invasive ventilation for more than 24 h in terms of ventilator free-days and being alive at day 28.

METHODS

The "effect of lung ultrasound-guided fluid deresuscitation on duration of ventilation in intensive care unit patients" (CONFIDENCE) is a national, multicentre, open-label, randomised controlled trial (RCT) in adult critically ill patients that are expected to be invasively ventilated for at least 24 h. Patients with conditions that preclude a negative fluid balance or LUS examination are excluded. CONFIDENCE will operate in 10 ICUs in the Netherlands and enrol 1000 patients. After hemodynamic stabilisation, patients assigned to the intervention will receive daily LUS with fluid balance recommendations. Subjects in the control arm are deresuscitated at the physician's discretion without the use of LUS. The primary endpoint is the number of ventilator-free days and being alive at day 28. Secondary endpoints include the duration of invasive ventilation; 28-day mortality; 90-day mortality; ICU, in hospital and total length of stay; cumulative fluid balance on days 1-7 after randomisation and on days 1-7 after start of LUS examination; mean serum lactate on days 1-7; the incidence of reintubations, chest drain placement, atrial fibrillation, kidney injury (KDIGO stadium ≥ 2) and hypernatremia; the use of invasive hemodynamic monitoring, and chest-X-ray; and quality of life at day 28.

DISCUSSION

The CONFIDENCE trial is the first RCT comparing the effect of LUS-guided deresuscitation to routine care in invasively ventilated ICU patients. If proven effective, LUS-guided deresuscitation could improve outcomes in some of the most vulnerable and resource-intensive patients in a manner that is non-invasive, easy to perform, and well-implementable.

TRIAL REGISTRATION

ClinicalTrials.gov NCT05188092. Registered since January 12, 2022.

摘要

背景

液体疗法是危重症患者的常见干预措施。人们越来越认识到,去复苏是液体疗法的一个重要组成部分,延迟去复苏与更长时间的有创通气和重症监护病房(ICU)住院时间延长有关。然而,最佳的去复苏时机和速度仍不清楚。肺部超声(LUS)可用于识别液体超负荷。我们假设,与没有肺部超声指导的去复苏相比,在预计需要进行 24 小时以上有创通气的危重症患者中,每日肺部超声指导的去复苏在无呼吸机天数和第 28 天存活方面更具优势。

方法

“肺部超声指导的液体去复苏对 ICU 患者通气时间的影响”(CONFIDENCE)是一项全国性、多中心、开放标签、随机对照试验(RCT),纳入预计需要进行至少 24 小时有创通气的成年危重症患者。排除了那些不能实现液体负平衡或不能进行肺部超声检查的患者。CONFIDENCE 将在荷兰的 10 个 ICU 中进行,共纳入 1000 名患者。在血流动力学稳定后,干预组的患者将接受每日肺部超声检查,并根据液体平衡情况提出建议。对照组的患者则由医生根据需要进行去复苏,不使用肺部超声。主要终点是无呼吸机天数和第 28 天存活。次要终点包括有创通气时间;28 天死亡率;90 天死亡率;ICU、住院和总住院时间;随机化后第 1-7 天和开始肺部超声检查后第 1-7 天的累积液体平衡;随机化后第 1-7 天的平均血清乳酸水平;再插管、胸腔引流、心房颤动、肾损伤(KDIGO 分期≥2)和高钠血症的发生率;有创血流动力学监测和胸部 X 线的使用;以及第 28 天的生活质量。

讨论

CONFIDENCE 试验是第一项比较肺部超声指导的去复苏与常规护理对接受有创通气的 ICU 患者影响的 RCT。如果证明有效,肺部超声指导的去复苏可以改善最脆弱和资源最密集的患者的预后,且这种方法是非侵入性的、易于操作的,并且易于实施。

试验注册

ClinicalTrials.gov NCT05188092。于 2022 年 1 月 12 日注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f369/10039569/65903044a3db/13063_2023_7171_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验